ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2006
Bisphosphonates for malignancy-related bone disease: current status, future developments.
Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol.Clinical oral investigations · 2018Pooled it
- Novel Approaches to Monitor Pharmacokinetics and Metabolism of Gemcitabine-Ibandronate Conjugate in Mice and Dogs.Molecules (Basel, Switzerland) · 2025Article
- Alterations in macrophage polarization in the craniofacial and extracranial skeleton after zoledronate application and surgical interventions - anFrontiers in immunology · 2023Article
- Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer.International journal of molecular sciences · 2021Review
- Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss.British journal of clinical pharmacology · 2019Review
- Sclerostin Modulation Holds Promise for Dental Indications.Healthcare (Basel, Switzerland) · 2018Review
- Analysis of orthopedic surgery of patients with metastatic bone tumors and pathological fractures.The Journal of international medical research · 2018Article
- Geranylgeranyl diphosphate synthase inhibition induces apoptosis that is dependent upon GGPP depletion, ERK phosphorylation and caspase activation.Cell death & disease · 2017Article
- γδ T cells in cancer immunotherapy.Oncotarget · 2017Review
- Targeting bone metastases in prostate cancer: improving clinical outcome.Nature reviews. Urology · 2015Review
- Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.Investigational new drugs · 2012Article
- Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice.Clinical & experimental metastasis · 2011Article
- Article
- Osteoclast-targeting small molecules for the treatment of neoplastic bone metastases.Cancer science · 2009Review
- Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer.Journal of pain and symptom management · 2008Article
- A primer of bone metastases management in breast cancer patients.Current oncology (Toronto, Ont.) · 2008Article
- Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2007Review
- Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.Cancer research · 2007Article
- Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner.Blood · 2007Article
- Multiple myeloma/hypercalcemia.Arthritis research & therapy · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review relates to the efficacy and safety of bisphosphonates in metastatic bone disease. It discusses practical recommendations and possible future indications for bisphosphonate therapy. The current aims of bisphosphonates for metastatic bone disease are to prevent skeletal-related events (SREs), reduce bone pain and improve quality of life. Phase III clinical trials of clodronate and pamidronate have established their efficacy against bone complications in patients with breast cancer and multiple myeloma, while randomized trials have shown SRE reductions with zoledronic acid in patients with breast cancer and multiple myeloma, prostate cancer, and lung and other solid tumors. These bisphosphonates also have some effect on metastatic bone pain. Ibandronate is a new aminobisphosphonate, available in more than 40 countries outside of the US as intravenous and oral formulations for the prevention of skeletal events in patients with breast cancer and bone metastases. Phase III studies have shown that both intravenously and orally administered ibandronate have efficacy for the prevention of skeletal events and for the reduction of metastatic bone pain. In addition to efficacy, the long-term tolerability of bisphosphonates in metastatic bone disease influences drug selection. Besides their use in patients with established bone metastases, recent and ongoing research suggests that bisphosphonates also have clinical benefit in the adjuvant setting, and for the treatment of cancer-treatment-induced bone loss. Such interesting new developments may underpin a new era of bisphosphonate use sometime in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.